Search results for "Ergolines"

showing 10 items of 18 documents

Dysregulated genes and their functional pathways in luteinized granulosa cells from PCOS patients after cabergoline treatment

2018

Polycystic ovarian syndrome (PCOS) is a common reproductive disorder frequently associated with a substantial risk factor for ovarian hyperstimulation syndrome (OHSS). Dopamine receptor 2 (D2) agonists, like cabergoline (Cb2), have been used to reduce the OHSS risk. However, lutein granulosa cells (LGCs) from PCOS patients treated with Cb2 still show a deregulated dopaminergic tone (decreased D2 expression and low dopamine production) and increased vascularization compared to non-PCOS LGCs. Therefore, to understand the PCOS ovarian physiology, it is important to explore the mechanisms that underlie syndrome based on the therapeutic effects of Cb2. Here, LGCs from non-PCOS and PCOS patients …

0301 basic medicineAdultEmbryologymedicine.medical_specialtyendocrine systemCabergolineendocrine system diseasesOvarian hyperstimulation syndromeAKT103 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicineCabergolineLuteal CellsmedicineHumansErgolines030219 obstetrics & reproductive medicineGranulosa Cellsbusiness.industryDopaminergicOvaryObstetrics and Gynecologynutritional and metabolic diseasesCell Biologymedicine.diseasefemale genital diseases and pregnancy complicationsVascular endothelial growth factorVascular endothelial growth factor A030104 developmental biologyEndocrinologyReproductive MedicinechemistryGene Expression RegulationDopamine receptorDopaminergic synapseCase-Control StudiesDopamine AgonistsFemalebusinessTranscriptomeBiomarkersmedicine.drugPolycystic Ovary Syndrome
researchProduct

Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin lev…

2013

OBJECTIVE: Currently available studies that fully analyse the metabolic parameters in patients with prolactinoma are scarce and discordant. The aim of this study was to evaluate the metabolic effects of cabergoline (CAB) treatment in patients with newly diagnosed prolactinoma in relation to disease control and CAB dosage. DESIGN: This is a retrospective clinical-based therapy analysis. PATIENTS: Forty-three patients with prolactinoma (eight men, 35 women), aged 33·65 ± 11·23 years, were evaluated metabolically at baseline and after 12 months of CAB treatment. MEASUREMENTS: Body mass index (BMI), systolic and diastolic blood pressure, waist circumference (WC), lipid profile, haemoglobinA1c (…

AdultBlood GlucoseMalemedicine.medical_specialtyCabergolineEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPituitary neoplasmSettore MED/13 - EndocrinologiaBody Mass IndexYoung AdultEndocrinologyInsulin resistanceInternal medicineCabergolineMedicineHumansPituitary NeoplasmsProlactinomaErgolinesProlactinomaAdiposityRetrospective Studiesmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryInsulinmedicine.diseaseLipidsProlactinBlood pressureEndocrinologyDopamine AgonistsMetabolomeFemaleInsulin ResistanceWaist CircumferencebusinessLipid profileBody mass indexmedicine.drugClinical endocrinology
researchProduct

Effect of Cabergoline on Metabolism in Prolactinomas.

2013

<b><i>Introduction:</i></b> Hyperprolactinemia has been implicated in the pathogenesis of obesity and glucose intolerance and is reportedly associated with an impaired metabolic profile. The current study aimed at investigating the effects of 12- and 60-month treatment with cabergoline (CAB) on metabolic syndrome (MetS) in patients with prolactinomas. <b><i>Patients and Methods:</i></b> 61 patients with prolactinomas (13 men, 48 women, 41 with microadenoma, 20 with macroadenoma), aged 34.4 ± 10.3 years, entered the study. In all patients, prolactin (PRL) and metabolic parameters were assessed at diagnosis and after 12 and 60 months of continuo…

AdultMalemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismTreatment outcomeprolactinomasAntineoplastic AgentsSettore MED/13 - EndocrinologiaPathogenesisCellular and Molecular NeuroscienceEndocrinologyInsulin resistanceMetabolic DiseasesCabergolineInternal medicinePrevalenceMedicineHumansInsulinPituitary NeoplasmsProspective StudiesErgolinesAdiposityMetabolic SyndromeDose-Response Relationship DrugEndocrine and Autonomic Systemsbusiness.industryPituitary tumorsMetabolismFastingmedicine.diseasePrognosisProlactinProlactinHyperprolactinemiaEndocrinologyTreatment OutcomeprolactinomacabergolineFemaleMetabolic syndromeInsulin Resistancebusinessmetabolismmedicine.drug
researchProduct

Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women und…

2007

Background Ovarian hyperstimulation syndrome (OHSS) is a result of ovarian overexpression of vascular endothelial growth factor (VEGF) and its receptor 2 (VEGFR2). VEGF/VEGFR2 binding disrupts cellular junctions and increases vascular permeability (VP), a characteristic of OHSS, but enhances angiogenesis, which is a fundamental step in implantation. In animals, the dopamine agonist Cabergoline (Cb2) prevents VP without affecting angiogenesis. In humans, Cb2 averts OHSS, but a possible detrimental effect on angiogenesis and implantation has not been explored. A pilot study was designed to analyze whether or not Cb2 administration, as a procedure for preventing OHSS, affects the outcome of as…

Adultmedicine.medical_specialtyCabergolinePregnancy RateReproductive Techniques AssistedOvarian hyperstimulation syndromePilot ProjectsBiologyDopamine agonistAndrologyOvarian Hyperstimulation Syndromechemistry.chemical_compoundPregnancyCabergolineInternal medicinemedicineHumansEmbryo ImplantationErgolinesOvarian follicleRetrospective StudiesPregnancyRehabilitationObstetrics and Gynecologymedicine.diseaseVascular endothelial growth factorPregnancy ratemedicine.anatomical_structureEndocrinologyReproductive MedicinechemistryDopamine AgonistsGestationFemalemedicine.drugHuman Reproduction
researchProduct

Locomotor and antidepressant-like effects of 5-HT(1A) agonist LY 228729 in prenatally benzodiazepine-exposed rats.

1998

Locomotor activity and antidepressant-like effect in the forced swim test (FST) of 5-HT(1A) agonist LY 228729 were investigated in adult rats prenatally exposed at doses of diazepam (DZ) and alprazolam (ALP) which induce persistent downregulation of GABA/ benzodiazepine (BZ) receptors. Prenatal exposure to ALP and DZ did not modify the efficacy of subchronic LY 228729 to decrease immobility time in the FST. Prenatal DZ and ALP potentiated the facilitatory effect of subchronic LY 228729 on locomotor activity; prenatal DZ was more effective than prenatal ALP. Moreover, prenatal DZ increased stereotypic movements induced by LY 228729. These data suggest that the persistent downregulation of GA…

AgonistMalemedicine.drug_classInjections SubcutaneousPharmacologyMotor ActivityRats Sprague-DawleyDownregulation and upregulationPregnancymedicineAnimalsPharmacology (medical)ErgolinesReceptorBiological Psychiatry5-HT receptorSwimmingPharmacologyBenzodiazepineDepressive DisorderDiazepamAlprazolamChemistrymusculoskeletal neural and ocular physiologyAntidepressive AgentsRatsSerotonin Receptor AgonistsPsychiatry and Mental healthNeurologyAlprazolamAnti-Anxiety AgentsPrenatal Exposure Delayed EffectsFemaleNeurology (clinical)Stereotyped Behaviorhuman activitiesDiazepammedicine.drugBehavioural despair testEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Perinatal exposure to 5-methoxytryptamine, behavioural-stress reactivity and functional response of 5-HT1A receptors in the adolescent rat.

2008

Abstract Serotonin is involved in a wide range of physiological and patho-physiological mechanisms. In particular, 5-HT1A receptors are proposed to mediate stress-adaptation. The aim of this research was to investigate in adolescent rats: first, the consequences of perinatal exposure to 5-metoxytryptamine (5MT), a 5-HT1/5-HT2 serotonergic agonist, on behavioural-stress reactivity in elevated plus maze, open field and forced swim tests; secondly, whether the behavioural effects induced by perinatal exposure to 5MT on open field and forced swim tests were affected by the selective 5-HT1A receptor agonist LY 228729, a compound able to elicit a characteristic set of motor behaviours on these ex…

AgonistMalemedicine.medical_specialtyElevated plus mazePerinatal 5MTOffspringmedicine.drug_classPyridinesPresynaptic TerminalsAnxietyMotor ActivitySerotonergicOpen fieldPiperazinesStatistics Nonparametric5-MethoxytryptamineBehavioral NeuroscienceSerotonin AgentsSex FactorsPregnancyBehavioural-stress reactivityInternal medicinemedicineAdolescent ratAnimals5-HT1A receptorErgolinesRats WistarAnalysis of VariancePerinatal 5MT; 5-HT1A receptors; Acute LY 228729 and WAY 100635; Behavioural-stress reactivity; Adolescent ratPerinatal ExposureBrainDrug SynergismRatsEndocrinologyAnimals NewbornPrenatal Exposure Delayed EffectsReceptor Serotonin 5-HT1ASynapsesSettore BIO/14 - FarmacologiaExploratory BehaviorAcute LY 228729 and WAY 100635FemaleSerotoninPsychologyStress PsychologicalBehavioural despair testBehavioural brain research
researchProduct

Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF r…

2006

No specific treatment is available for ovarian hyperstimulation syndrome (OHSS), the most important complication in infertile women treated with gonadotropins. OHSS is caused by increased vascular permeability (VP) through ovarian hypersecretion of vascular endothelial growth factor (VEGF)activating VEGF receptor 2 (VEGFR-2). We previously demonstrated in an OHSS rodent model that increased VP was prevented by inactivating VEGFR-2 with a receptor antagonist(SU5416).However,duetoitstoxicity(thromboembolism) and disruption of VEGFR-2-dependent angiogenic processes critical for pregnancy, this kind of compound cannot be used clinically to prevent OHSS. Dopamine receptor 2 (Dp-r2) agonists, use…

AgonistVascular Endothelial Growth Factor Amedicine.medical_specialtyCabergolinemedicine.drug_classAngiogenesisOvarian hyperstimulation syndromeNeovascularization PhysiologicBiologyDopamine agonistCapillary Permeabilitychemistry.chemical_compoundOvarian Hyperstimulation SyndromeEndocrinologyCorpus LuteumInternal medicineCabergolinemedicineAnimalsRNA MessengerErgolinesPhosphorylationRats WistarReceptors Dopamine D2Kinase insert domain receptorReceptor antagonistmedicine.diseaseVascular Endothelial Growth Factor Receptor-2RatsVascular endothelial growth factorDisease Models AnimalEndocrinologychemistryDopamine AgonistsFemalemedicine.drugEndocrinology
researchProduct

The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis

2011

Implantation of a retrogradely shed endometrium during menstruation requires an adequate blood supply, which allows the growth of endometriotic lesions. This suggests that the development of endometriosis can be impaired by inhibiting angiogenesis. The growth of endometriotic foci is impaired by commercial oncological antiangiogenic drugs used to block vascular endothelial growth factor (VEGF) signaling. The dopamine agonist cabergoline (Cb2) inhibits the growth of established endometriosis lesions by exerting antiangiogenic effects through VEGFR2 inactivation. However, the use of ergot-derived Cb2 is associated with an increased incidence of cardiac valve regurgitation. To evaluate the pot…

Embryologymedicine.medical_specialtyCabergolineProliferation indexAngiogenesisEndometriosisEndometriosisCell CountPharmacologyDopamine agonistClavicepsNeovascularizationEndometriumMicechemistry.chemical_compoundEndocrinologyInternal medicineCabergolinemedicineAnimalsHumansErgolinesCell ProliferationUterine DiseasesNeovascularization PathologicReceptors Dopamine D2business.industryQuinagolideObstetrics and GynecologyCell Biologymedicine.diseaseVascular Endothelial Growth Factor Receptor-2Vascular endothelial growth factorDisease Models AnimalEndocrinologyReproductive MedicinechemistryDopamine AgonistsBlood VesselsFemalemedicine.symptombusinessmedicine.drugREPRODUCTION
researchProduct

Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction.

2007

Abstract Context: Ovarian hyperstimulation syndrome (OHSS) results from increased vascular permeability (VP) caused by ovarian hypersecretion of vascular endothelial growth factor (VEGF), which activates its receptor-2. In animals, the dopamine receptor 2 agonist cabergoline (Cb2) inactivates VEGF receptor-2 and prevents increased VP. Objective: Our objective was to test whether Cb2 reduces VP and prevents OHSS in humans. Design: We conducted a prospective, randomized, double-blind study on oocyte donors at risk of developing OHSS (>20 follicles, >12 mm developed, and >20 oocytes retrieved). Interventions: Cb2 0.5 mg/d (n = 37) or a placebo (n = 32) was administered fro…

Endocrinology Diabetes and MetabolismClinical BiochemistryOvarian hyperstimulation syndromeVascular permeabilityHematocritBiochemistrychemistry.chemical_compoundHemoglobinsEndocrinologyPregnancyAscitesImage Processing Computer-AssistedMedicineProspective Studiesmedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionObstetrics and GynecologyAscitesGeneral MedicineHemoconcentrationMagnetic Resonance ImagingVascular endothelial growth factorHematocritDopamine AgonistsFemalemedicine.symptommedicine.drugAgonistAdultmedicine.medical_specialtyCabergolinemedicine.drug_classContext (language use)Fertilization in VitroDopamine agonistOvarian Hyperstimulation SyndromeDouble-Blind MethodInternal medicineCabergolineLuteal CellsHumansErgolinesGranulosa Cellsbusiness.industryReceptors Dopamine D2Peritoneal fluidBiochemistry (medical)Ovarymedicine.diseaseEndocrinologychemistryRegional Blood FlowbusinessExtracellular SpaceThe Journal of clinical endocrinology and metabolism
researchProduct

Roquefortine C occurrence in blue cheese.

2001

Several strains of Penicillium are used for the production of mold-ripened cheeses, and some of them are able to produce mycotoxins. The aims of the research were the determination of roquefortine C and PR toxin in domestic and imported blue cheeses, the identification of the penicillia used as starter, and the investigation of their capacity for producing toxins in culture media. Roquefortine C was always found in the cheeses at levels ranging from 0.05 to 1.47 mg/kg, whereas the PR toxin was never found. The identification of the fungal strains present in the domestic cheeses included Penicillium glabrum, Penicillium roqueforti, and Penicillium cyclopium in the Gorgonzola "dolce" and Peni…

IndolesTime FactorsBlue cheeseNaphtholsBiologyMicrobiologyHeterocyclic Compounds 4 or More RingsPiperazineschemistry.chemical_compoundfoodCheeseYeast extractFood sciencefood.cheeseErgolinesMycotoxinPenicillium crustosumRoquefortine CChromatography High Pressure LiquidPenicilliumfood and beveragesPenicillium roquefortiMycotoxinsbiology.organism_classificationPenicillium glabrumchemistryPenicilliumFood ScienceJournal of food protection
researchProduct